血浆组蛋白对脓毒症患者预后的预测价值
该研究纳入93例脓毒症患者及同期健康志愿者,记录入ICU 24小时血浆组蛋白、cTnI、NT-proBNP、SOFA评分、乳酸、PCT及血管升压药使用等。ICU死亡29例,死亡率31.2%。死亡组血浆组蛋白、cTnI、SOFA评分及升压药使用比例均显著高于存活组;多因素分析显示升压药使用(OR=5.277,P=0.043)和组蛋白水平(OR=79.244,P=0.036)是死亡的独立危险因素。组蛋白预测预后的AUC为0.769,界值0.30 mg/L时敏感度72.4%、特异度81.2%。作者认为血浆组蛋白可作为预测脓毒症患者预后的指标。
要点
- 脓毒症患者入ICU 24小时血浆组蛋白死亡组0.33(0.28,0.45)mg/L vs 存活组0.22(0.17,0.29)mg/L,死亡组更高(P<0.05)。
- 多因素分析显示升压药使用(OR=5.277,P=0.043)和组蛋白水平(OR=79.244,P=0.036)是脓毒症患者ICU死亡的独立危险因素。
- 血浆组蛋白预测预后的AUC为0.769,界值0.30 mg/L时敏感度72.4%、特异度81.2%;SOFA评分AUC为0.653。
- 组蛋白>0.3 mg/L组ICU死亡率48.5%(16/33)vs ≤0.3 mg/L组21.7%(13/60),前组更高(P<0.05),两组ICU住院时间无统计学差异。
- 组蛋白与cTnI(r=0.577)、SOFA(r=0.469)、NT-proBNP(r=0.349)、乳酸(r=0.357)正相关,与PCT无显著相关(r=0.133,P=0.205)。
适用人群与场景
- 2016年5月至2018年6月入住扬州大学附属苏北人民医院ICU的脓毒症患者93例,同期健康志愿者为健康对照。
诊断标准与关键阈值
- 以血浆组蛋白0.30 mg/L为预测预后的界值,敏感度72.4%、特异度81.2%。
- SOFA评分预测预后的界值为10.50,敏感度58.6%、特异度70.3%。
研究设计与关键结果
- 单中心研究纳入93例脓毒症患者,ICU死亡29例,死亡率31.2%。
- 死亡组vs存活组:组蛋白0.33(0.28,0.45)mg/L vs 0.22(0.17,0.29)mg/L,cTnI 0.25±0.13 μg/L vs 0.20±0.08 μg/L,SOFA 11(8,12)vs 9(8,11),升压药使用比例93.1%(27/29)vs 68.8%(44/64),均P<0.05。
- 多因素二元Logistic回归显示升压药使用(OR=5.277,P=0.043)和组蛋白水平(OR=79.244,P=0.036)是死亡的独立危险因素。
- 组蛋白与cTnI(r=0.577,P=0.000)、SOFA(r=0.469,P=0.000)、NT-proBNP(r=0.349,P=0.001)、乳酸(r=0.357,P=0.000)正相关,与PCT无显著相关(r=0.133,P=0.205)。
- ROC分析:组蛋白AUC 0.769(P=0.000);SOFA评分AUC 0.653(P=0.018);cTnI、NT-proBNP、乳酸和PCT对预后预测价值不大。
- 组蛋白>0.3 mg/L组vs ≤0.3 mg/L组:SOFA 11(10,12)vs 9(8,10),升压药使用84.8%(28/33)vs 76.7%(46/60),cTnI 0.28(0.19,0.32)μg/L vs 0.18(0.12,0.22)μg/L,NT-proBNP 3624.0(2800.0,5260.0)ng/L vs 2512.0(1361.8,3590.8)ng/L,乳酸2.25(1.85,3.50)mmol/L vs 1.60(1.25,2.35)mmol/L,PCT 2.10(1.30,4.03)μg/L vs 1.60(1.26,2.33)μg/L,ICU死亡率48.5%(16/33)vs 21.7%(13/60),均P<0.05;两组ICU住院时间无统计学差异。
证据类型、等级与局限
- 证据类型:单中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为血浆组蛋白可作为预测脓毒症患者预后的指标。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the value of plasma histones in predicting the prognosis of sepsis patients.
METHODS: The patients with sepsis admitted to intensive care unit (ICU) of Subei People's Hospital of Jiangsu Province Affiliated to Yangzhou University from May 2016 to June 2018 were enrolled as the research subjects, and healthy volunteers were selected as healthy control at the same period. The plasma levels of histones, cardiac troponin I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), sequential organ failure assessment (SOFA) score, lactate (Lac), procalcitonin (PCT) on admission 24 hours, and use of vasoconstrictor agents, the length of ICU stay and ICU mortality were recorded. The patients were divided into survival group and death group according to the prognosis, and the differences of each index between the two groups were compared. Multivariate binary Logistic regression analysis was carried out to identify the independent risk factors of death. The correlation between histone and the levels of cTnI, NT-proBNP, PCT and Lac was analyzed. The value of plasma histone, cTnI, NT-proBNP, PCT and Lac in predicting the prognosis of patients was analyzed by receiver operating characteristic (ROC) curve. According to the threshold value of histone in predicting prognosis, the patients were divided into two groups, and the differences of various indicators between the two groups were compared.
RESULTS: (1) A total of 93 sepsis patients were included, with 29 cases of ICU death, and the mortality was 31.2%. (2) Compared with the healthy control group, histones, cTnI, NT-proBNP were significant increased, besides, histones, cTnI in the death group were further increased compared with the survival group; in addition, SOFA, proportion of vasoconstrictor use were also significant higher than those in the survival group [histones (mg/L): 0.33 (0.28,0.45) vs. 0.22 (0.17,0.29), cTnI (μg/L): 0.25±0.13 vs. 0.20±0.08, SOFA: 11 (8, 12) vs. 9 (8, 11), the rate of vasopressor use: 93.1% (27/29) vs. 68.8% (44/64), all P < 0.05]. Statistically significant indicators between the two groups were included in multivariate binary Logistic regression analysis. The result showed that the independent risk factors affecting the prognosis of patients were the rate of vasopressor use [odds ratio (OR) = 5.277, P = 0.043] and the level of histone (OR = 79.244, P = 0.036). (3) The plasma histone level were positively correlated with cTnI (r = 0.577, P = 0.000), SOFA (r = 0.469, P = 0.000), NT-proBNP (r = 0.349, P = 0.001) and Lac (r = 0.357, P = 0.000), while there was no significant correlation between histone and PCT (r = 0.133, P = 0.205). (4) ROC curve analysis showed that the area under ROC curve (AUC) of histone predicting prognosis was 0.769 (P = 0.000); when the cut-off point was 0.30 mg/L, the sensitivity and specificity were 72.4% and 81.2% respectively. The AUC of SOFA score was 0.653 (P = 0.018), and the sensitivity and specificity were 58.6% and 70.3% respectively when the cut-off point was 10.50; while cTnI, NT-proBNP, Lac and PCT had little value in predicting the prognosis of patients. (5) Compared with the group with histone level lower than 0.3 mg/L, the group with histones level greater than 0.3 mg/L had higher SOFA score, more doses of vasopressor, higher cTnI, NT-proBNP, Lac and PCT levels, and higher ICU mortality [SOFA: 11 (10, 12) vs. 9 (8, 10), use of vasopressor: 84.8% (28/33) vs. 76.7% (46/60), cTnI (μg/L): 0.28 (0.19, 0.32) vs. 0.18 (0.12, 0.22), NT-proBNP (ng/L): 3 624.0 (2 800.0, 5 260.0) vs. 2 512.0 (1 361.8, 3 590.8), Lac (mmol/L): 2.25 (1.85, 3.50) vs. 1.60 (1.25, 2.35), PCT (μg/L): 2.10 (1.30, 4.03) vs. 1.60 (1.26, 2.33), ICU mortality: 48.5% (16/33) vs. 21.7% (13/60), all P < 0.05], while no statistical difference in the length of ICU stay was found.
CONCLUSIONS: The independent risk factors for ICU mortality of sepsis patients were high histone level and the use of vasopressor. Plasma histone can be regarded as an indicator in predicting the prognosis of patients with sepsis.
参考来源
- Lu N, Jiang L, Zhu B, et al. [Prediction value of plasma histone in prognosis of sepsis patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31315721. doi:10.3760/cma.j.issn.2095-4352.2019.06.003
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。